Combination chemotherapy with irinotecan hydrochloride (CPT-11) and mitomycin C in platinum-refractory ovarian cancer
Combination chemotherapy with irinotecan hydrochloride (CPT-11) and mitomycin C in platinum-refractory ovarian cancer
复制标题
DOI：
10.1097/01.coc.0000128630.26754.fb
复制
发表时间：
2004-10-01
影响因子：
2.6
通讯作者：
Tanaka, K
中科院分区：
文献类型：
--
作者：
Aoki, Y;Kurata, H;Tanaka, K
本研究的目的是检查盐酸伊立替康（CPT-11）和丝裂霉素C（MMC）联合化疗在铂类药物难治性卵巢癌患者中的活性水平。患者在第1、15、29天接受CPT-11（140 mg/m2）联合MMC（7 mg/m2）治疗，直至疾病进展、出现不可接受的毒性或选择停止治疗。总体而言，13例患者接受了61个周期的CPT-11/MMC化疗。该方案的主要毒副反应为中性粒细胞减少，时间短且可逆。3级和4级中性粒细胞减少的发生率分别为46%（6/13）和15%（2/13）。非血液学毒性通常为轻度且耐受性良好。在13例患者中，4例（31%）出现客观缓解（1例CR，3例PR）。在应答者中，中位应答持续时间为30周（范围：12至292+周）。在本试验中接受治疗的13例患者的中位至进展时间为24周（范围：8至292+周），中位生存期为36周（范围：20至292+周）。这项初步研究表明，CPT-11和MMC的组合似乎是难治性卵巢癌患者的一个积极的方案。
The aim of this study was to examine the level of activity of irinotecan hydrochloride (CPT-11) and mitomycin-C (MMC) combination chemotherapy in a patient population with platinum-refractory ovarian cancer. Patients received CPT-11 (140 mg/m(2)) in combination with MMC (7 mg/m(2)) on days 1, 15, 29 until disease progression, unacceptable toxicity developed, or they elected to discontinue treatment. Overall, 61 cycles of CPT-11/MMC chemotherapy were delivered to 13 patients. The major toxicity with this regimen was neutropenia, which was brief and reversible. The incidences of grade 3 and 4 neutropenia were 46% (6/13) and 15% (2/13), respectively. The nonhematological toxicities were generally mild and well tolerated. Of the 13 patients, 4 (31%) experienced an objective response (1 CR, 3 PRs). Among responders, the median duration of response was 30 weeks (range, 12 to 292+ weeks). The median time to progression for the 13 patients who received treatment on this trial was 24 weeks (range, 8 to 292+ weeks), with a median survival of 36 weeks (range, 20 to 292+ weeks). This preliminary study shows that the combination of CPT-11 and MMC appears to be an active regimen in patients with refractory ovarian cancer.